July 2021: Breyanzi (Lisocabtagene maraleucel; liso-cel), chinyorwa cheCD19-chinotungamirirwa chimeric antigen receptor (CAR) T kurapwa kwemasero yakataurwa Bristol Myers squibb (BMS), yakagamuchirwa neUS Food and Drug Administration (USFDA).
CAR-T cell kurapa imhando ye immunotherapy inoshanda nekushandura T masero emunhu kuti azive uye aparadze cancer maseru.
Breyanzi, inoveli CD19-inotungamirwa chimeric antigen receptor (CAR) T cell kurapwa yakagadziriswa naBristol Myers Squibb (BMS), yakabvumidzwa ne US Chikafu uye Dzvinyu Dhiza (USFDA) (Lisocabtagene maraleucel; liso-cel).
Verenga zvakare: CAR T-Cell kurapa muIndia
Varwere vakura vakadzokazve kana kuramba (R / R) hombe B-cell lymphoma (LBCL) mushure memitsetse miviri kana kupfuura yemaitiro ehurongwa acharapwa neiyo nyowani CAR T cell kurapa. There are several types of LBCL, such as primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, follicular lymphoma grade 3B, and DLBCL not otherwise described, which can also develop from indolent lymphoma.
Kenza yeDLBCL ndiyo inowanzoitika mhando yeasina-Hodgkin lymphoma (NHL), uye chirwere chinotyisa umo 73 muzana yevarwere vasingateerere kurapwa kana kudzoka.
Breyanzi, kune rimwe divi, haina kukurudzirwa kuvarwere vane primary central nervous system lymphoma, kunyangwe iri mishonga inogona kurapa.
Uyewo verenga: CAR T-Cell kurapa muChina
Breyanzi, a CAR T cell kurapa, will be very important in clinical practice, giving people with relapsed or refractory large B-cell lymphoma the chance for a long-lasting response with a personalized treatment experience, said Samit Hirawat, chief medical officer at Bristol Myers Squibb. Our unwavering commitment to advancing cell therapy research, providing breakthrough medicines, and supporting patients at every step of their treatment journey is reflected in the FDA approval.”
Breyanzi aive nezvikamu makumi manomwe nezvitatu kubva muzana zvekupindura uye chikamu che73 muzana chakapindurwa (CR) muchikamu cheTRANSCEND NHL 54, yaive muyedzo wakakura kwazvo mu001L + LBCL.
BMS’ immunotherapy manufacturing plant in Bothell, Washington, will produce the novel cell treatment.
CAR T-Cell kurapa muIndia is in the clinical trials stage, and hopefully it will be available very soon for commercial use.
